Silo Pharma (NASDAQ: SILO) has taken a pivotal step in the development of treatments for Alzheimer's disease by filing a patent application with the U.S. Patent and Trademark Office for SPC-14. This novel intranasal compound, exclusively licensed from Columbia University, targets cognitive and neuropsychiatric symptoms associated with Alzheimer's. The patent application underscores SPC-14's unique mechanism of action, focusing on the glutamate receptor NDMAR and serotonin 5-HT4, with preclinical studies indicating potential improvements in cognitive memory function.
The significance of this development extends beyond the immediate implications for Alzheimer's treatment. It represents a critical component of Silo Pharma's broader intellectual property strategy, aimed at safeguarding its innovative drug platforms. The company's focus on developing traditional and psychedelic therapies in novel formulations and drug-delivery systems positions it as a leader in addressing underserved conditions, including stress-induced psychiatric disorders, chronic pain, and central nervous system diseases.
Silo Pharma's pipeline includes several promising programs, such as SPC-15 for PTSD and stress-induced anxiety disorders, SP-26 for fibromyalgia and chronic pain relief, and SPU-16 for multiple sclerosis. The advancement of SPC-14 into the patent application phase not only highlights the company's commitment to groundbreaking research but also its potential to make a lasting impact on the cannabis and psychedelic industries. For more details on Silo Pharma's initiatives, visit https://www.SiloPharma.com.
